SOUTH PLAINFIELD, N.J., Aug. 30, 2023 /PRNewswire/ -- PTC Therapeutics (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Citi 2023 18th Annual BioPharma Conference
Wednesday, Sept. 6, at 9:40 a.m. EDT
Morgan Stanley 21st Annual Global Healthcare Conference 2023
Monday, Sept. 11, at 1:35 p.m. EDT
2023 Cantor Global Healthcare Conference
Tuesday, Sept. 26, at 12:25 p.m. EDT
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
For More Information:
Investors:
Kylie O'Keefe
+1 (908) 300-0691
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Jeanine Clemente
+1 (908) 912-9406
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$46.41 |
| Daily Change: | -0.53 -1.13 |
| Daily Volume: | 696,910 |
| Market Cap: | US$3.580B |
February 27, 2025 February 19, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
